DELETERIOUS INFLUENCE OF PYRAZINAMIDE ON THE OUTCOME OF PATIENTS WITH FULMINANT OR SUBFULMINANT LIVER-FAILURE DURING ANTITUBERCULOUS TREATMENT INCLUDING ISONIAZID

DELETERIOUS INFLUENCE OF PYRAZINAMIDE ON THE OUTCOME OF PATIENTS WITH FULMINANT OR SUBFULMINANT LIVER-FAILURE DURING ANTITUBERCULOUS TREATMENT INCLUDING ISONIAZID
复制标题

DOI：
10.1016/0270-9139(95)90236-8
复制
发表时间：
1995-04-01
期刊：
HEPATOLOGY
影响因子：
13.5
通讯作者：
BENHAMOU, JP
BENHAMOU, JP
中科院分区：
医学1区
文献类型：
--
作者：
DURAND, F;BERNUAU, J;BENHAMOU, JP

文献摘要

被引文献

相似文献

异烟肼和吡嗪酰胺是众所周知的肝毒性药物，通常联合使用。本研究的目的是评估吡嗪酰胺对抗结核治疗引起的暴发性或亚暴发性肝衰竭预后的影响。本文报告18例抗结核治疗引起的暴发性或亚暴发性肝衰竭患者。9例患者接受了异烟肼和利福平联合吡嗪酰胺治疗（第1组），9例患者接受了异烟肼和利福平联合吡嗪酰胺治疗（第2组）。暴发性和亚暴发性肝功能衰竭的严重程度，根据昏迷的发生率和因子V的最低水平来判断，在两组中相似。第1组的自发存活率（8/9）高于第2组（2/9）（P <0.02）。作者得出结论，吡嗪酰胺联合给药与抗结核治疗期间发生的暴发性或亚暴发性肝炎患者的死亡率增加相关。在这些患者中，吡嗪酰胺给药和抗结核治疗开始与黄疸之间的间隔超过15天，结合III级脑病和因子V低于20%，预测无需肝移植即可死亡。
Isoniazid and pyrazinamide are well-known hepatotoxic drugs, often used in combination. The aim of this study was to assess the prognostic influence of pyrazinamide on the outcome of fulminant or subfulminant liver failure caused by antituberculous therapy. Eighteen patients with fulminant or subfulminant liver failure due to antituberculous therapy were studied. Nine patients received isoniazid and rifampicin without pyrazinamide (group 1), and nine patients received isoniazid and rifampicin together with pyrazinamide (group 2). The severity of fulminant and subfulminant liver failure, as judged by the prevalence of coma and the lowest level of factor V, was similar in the two groups. Spontaneous survival was greater in group 1 (eight of nine) than in group 2 (two of nine) (P < .02). The authors conclude that pyrazinamide co-administration was associated with an increased mortality in patients with fulminant or subfulminant hepatitis occurring during antituberculous therapy, In these patients, pyrazinamide administration and an interval of more than 15 days between the onset of antituberculous treatment and jauudice, combined with grade III encephalopathy and factor V below 20%, predicted death without liver transplantation.